These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16541750)

  • 1. [Incremental effect and mechanism of cyclosporine on blood concentration of statins and statin package insert information in Japan].
    Hirata-Koizumi M; Saito M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):37-40. PubMed ID: 16541750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.
    Neuvonen PJ; Niemi M; Backman JT
    Clin Pharmacol Ther; 2006 Dec; 80(6):565-81. PubMed ID: 17178259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
    Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
    J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole.
    Maxa JL; Melton LB; Ogu CC; Sills MN; Limanni A
    Ann Pharmacother; 2002 May; 36(5):820-3. PubMed ID: 11978159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Controversy in Transplantation: Tacrolimus Versus Cyclosporine in Statin Drug Interactions.
    Migliozzi DR; Asal NJ
    Ann Pharmacother; 2020 Feb; 54(2):171-177. PubMed ID: 31441337
    [No Abstract]   [Full Text] [Related]  

  • 6. HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview.
    Balasubramanian R; Maideen NMP
    Curr Drug Metab; 2021; 22(5):328-341. PubMed ID: 33459228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
    Simonson SG; Raza A; Martin PD; Mitchell PD; Jarcho JA; Brown CD; Windass AS; Schneck DW
    Clin Pharmacol Ther; 2004 Aug; 76(2):167-77. PubMed ID: 15289793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
    Neuvonen PJ
    Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine markedly raises the plasma concentrations of repaglinide.
    Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
    Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration.
    Gupta A; Harris JJ; Lin J; Bulgarelli JP; Birmingham BK; Grimm SW
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5986-94. PubMed ID: 27458210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-drug interactions that interfere with statin metabolism.
    Hirota T; Ieiri I
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1435-47. PubMed ID: 26058399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
    Williams D; Feely J
    Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.
    Treiber A; Schneiter R; Häusler S; Stieger B
    Drug Metab Dispos; 2007 Aug; 35(8):1400-7. PubMed ID: 17496208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of statins: focus on clinical pharmacokinetics and drug interactions.
    Bellosta S; Paoletti R; Corsini A
    Circulation; 2004 Jun; 109(23 Suppl 1):III50-7. PubMed ID: 15198967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
    Evans M; Rees A
    Drug Saf; 2002; 25(9):649-63. PubMed ID: 12137559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin regulation of CYP3A4 and CYP3A5 expression.
    Willrich MA; Hirata MH; Hirata RD
    Pharmacogenomics; 2009 Jun; 10(6):1017-24. PubMed ID: 19530969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flavonoid-statin interactions causing myopathy and the possible significance of OATP transport, CYP450 metabolism and mevalonate synthesis.
    Zechner J; Britza SM; Farrington R; Byard RW; Musgrave IF
    Life Sci; 2022 Feb; 291():119975. PubMed ID: 34560084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.
    Park JW; Siekmeier R; Lattke P; Merz M; Mix C; Schüler S; Jaross W
    J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):351-61. PubMed ID: 11907637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New strategies to address drug-drug interactions involving OATPs.
    Poirier A; Funk C; Lavé T; Noé J
    Curr Opin Drug Discov Devel; 2007 Jan; 10(1):74-83. PubMed ID: 17265745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy.
    Eng H; Scialis RJ; Rotter CJ; Lin J; Lazzaro S; Varma MV; Di L; Feng B; West M; Kalgutkar AS
    Drug Metab Dispos; 2016 May; 44(5):692-9. PubMed ID: 26888941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.